Celsion (CLSN) Announces Publication of ThermoDox Study Results in Radiology
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/15/2024
- Stocks close lower as Middle East tensions, Treasury yields weigh
- Apple’s iPhone shipments dip 10% in Q1 as Samsung reclaims the top spot
- Tesla (TSLA) to cut over 10% global staff - Electrek
- Aluminum, Nickel, Copper: LME ban on Russian metal creates buying opportunity?
- Informatica (INFA) jumps as Salesforce (CRM) reportedly eyes new mega takeover
- Canoo Inc. (GOEV) Enters Preferred Shares Purchase Agreement
- Trump Media & Technology Group (DJT) Files S-1
- Tesla (TSLA) Senior VP Drew Baglino Is Said To Leave The Company - Bloomberg
- General Motors (GM) Said to be Moving Detroit HQ to Dan Gilbert's Hudson Tower - Bloomberg
- The Israeli Air Force Has Completed Its Preparation For An Imminent Attack Against Iran - Reuters
- After-hours movers: Tesla, Gildan Activewear, Macatawa Bank, and more
- Midday movers: Goldman Sachs and Meta Platforms rise; Apple and Tesla fall
- Nike, Alpine Immune Sciences rise premarket; CarMax, Robinhood and Regeneron fall
- After-hours movers: Alpine Immune Sciences, Costco, and more
- Midday movers: Delta, Taiwan Semiconductor rise; Hexcel falls
Celsion Announces Publication of ThermoDox® Study Results in Radiology
January 17, 2019 8:30 AM ESTPublication Highlights Phase I Data Supporting Safety and Feasibility of Treatment with ThermoDox® and Non-Invasive, Focused Ultrasound
University of Oxfords Findings Provide Additional Independent Evidence of ThermoDoxs Unique and Highly Effective Anti-Cancer Mechanism
LAWRENCEVILLE, N.J, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that results from the Phase I TARDOX... More
